ArticleAnnals of translational medicine2022

The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis.

Wei-Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.